Case Study

Greywolf Therapeutics

Making cancer cells visible to the immune system

Play the video Read More
Date posted: 07/08/2025

Oxford-based Greywolf Therapeutics is developing new treatments for cancer patients who currently have limited immunotherapy options. With support from Innovate UK’s Biomedical Catalyst and Cancer Therapeutics programmes, the company is focusing on colorectal cancer, the UK’s fourth most common cancer and second leading cause of cancer-related death.

The challenge

Colorectal cancer is becoming more common, especially in younger people. Unlike other cancers, it typically has a low tumour mutation burden, meaning fewer genetic changes for the immune system to detect. As a result, standard immunotherapies often fail to work, leaving patients reliant on invasive treatments like chemotherapy, surgery and radiotherapy.

Greywolf’s approach

Greywolf is tackling this challenge by enhancing how cancer cells present themselves to the immune system. Their therapy modulates ERAP-1, an enzyme that helps process proteins into peptides (small fragments that appear on the surface of cells). This modulation leads to novel peptides being expressed on the cell surface in increased abundance, meaning tumours are ‘illuminated’ and therefore more visible to T cells and the wider immune system.

Accelerating innovation with Innovate UK

We were so excited to get the extra grant funding from Innovate UK. It’s really helped us to accelerate the speed with which we can do our research.

“Funding in the sort of early research that we do is always hard to come by. So having that extra investment from Innovate UK has helped us do more experiments, produce more data and move our therapies faster towards the clinic than we would have been able to do otherwise.

Dr Tom Lillie, Chief Medical Officer

Related Content

Programme

This Case Study is part of Biomedical Catalyst.

Accelerating the translation of innovative ideas and discoveries into healthcare solutions that improve lives. The Biomedical Catalyst transforms innovative ideas into commercially viable businesses. It delivers sector growth, de-risks innovation and gets companies investment ready.

Find out more
Close

Connect with Innovate UK Business Connect

Join Innovate UK Business Connect's mailing list to receive updates on funding opportunities, events and to access Innovate UK Business Connect's deep expertise. Please check your email to confirm your subscription and select your area(s) of interest.